Caficrestat
Caficrestat (AT-001) is an orally active aldose reductase inhibitor. Caficrestat can be used in the study of diabetic cardiomyopathy[1][2].
Product Specifications
CAS Number
1355612-71-3
Product Name Alternative
AT-001; Aldose reductase-IN-1
UNSPSC
12352005
Target
Aldose Reductase
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/caficrestat.html
Purity
99.74
Solubility
DMSO : ≥ 28 mg/mL
Smiles
O=C1C2=NC=CN=C2C(CC(O)=O)=NN1CC3=NC4=C(C=CC(C(F)(F)F)=C4)S3
Molecular Formula
C17H10F3N5O3S
Molecular Weight
421.35
References & Citations
[1]Yepuri G, Kancharla K, Perfetti R, Shendelman S, Wasmuth A, Ramasamy R. The aldose reductase inhibitors AT-001, AT-003 and AT-007 attenuate human keratinocyte senescence. Front Aging. 2024 Dec 17;5:1466281.|[2]Gopal K, et ak. Aldose reductase inhibition alleviates diabetic cardiomyopathy and is associated with a decrease in myocardial fatty acid oxidation. Cardiovasc Diabetol. 2023 Mar 28;22 (1) :73.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 3
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
